Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an integrated biopharmaceutical company. The Company is focused on the development of therapies to treat cancer, inflammation, and other diseases. It operates a technology platform based on adenosine chemistry and biology. Its product pipeline includes Mipsagargin; A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B Dual Antagonist. The Company is developing Mipsagargin for different tumor types, including Hepatocellular carcinoma (liver cancer), Glioblastoma (brain cancer) and Prostate cancer. The other combinations of Mipsagargin include PD1/PDL1 combination and Xenograft models. The A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B dual antagonist are its adenosine receptor programs.
More about the company